Planet 13 Holdings (PLNH) Cost of Revenue (2021 - 2026)
Planet 13 Holdings' (PLNH) quarterly Cost of Revenue came in at $11.7 million in Q1 2026, down 27.12% year-on-year from $16.0 million in Q1 2025, and up 8657.21% on a QoQ basis from $133360.0 in Q4 2025.
Planet 13 Holdings (PLNH) Cost of Revenue (2021 - 2026) Analysis & Trends
Planet 13 Holdings (PLNH) has 6 years of Cost of Revenue data on file, last reported at $11.7 million in Q1 2026.
- On a quarterly basis, Cost of Revenue fell 27.12% year-over-year to $11.7 million in Q1 2026; TTM through Mar 2026 was $12.2 million, a 74.95% decrease from a year earlier, with the FY2025 full-year figure at $870288.0, down 98.56% from the prior year.
- Cost of Revenue for Q1 2026 stood at $11.7 million, up from $133360.0 in the prior quarter.
- Over the last five years, Cost of Revenue for PLNH reached as high as $17.2 million in Q4 2024 and fell as low as $99117.0 in Q2 2024.
- Historically, Cost of Revenue has averaged $6.1 million across 5 years, with a median of $408404.0 in 2023.
- Across the five-year window, Cost of Revenue slumped 99.29% in 2024 and surged 6554.06% in 2025, its largest moves.
- Year by year, Cost of Revenue stood at $14.2 million in 2022, then sank by 96.87% to $443500.0 in 2023, then surged by 3776.2% to $17.2 million in 2024, then plunged by 99.22% to $133360.0 in 2025, then jumped by 8657.21% to $11.7 million in 2026.
- Per Business Quant data, the three most recent Cost of Revenue figures were $11.7 million in Q1 2026, $133360.0 in Q4 2025, and $200787.0 in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | 2.01 Bn |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | 641.00 Mn |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | 2.59 Bn |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | 133.40 Mn |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | 2.36 Bn |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | 13.80 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | 586.00 Mn |
| 10 | Planet 13 Holdings | 39.42 Mn | 23.16 Mn | 9.41 Mn | 11.68 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 11.68 Mn |
| Mar 31, 2026 | 11.68 Mn |
| Dec 31, 2025 | 133,360.00 |
| Dec 31, 2025 | 133,360.00 |
| Sep 30, 2025 | 200,787.00 |
| Sep 30, 2025 | 200,787.00 |
| Jun 30, 2025 | 206,544.00 |
| Jun 30, 2025 | 206,544.00 |
| Mar 31, 2025 | 16.02 Mn |
| Mar 31, 2025 | 16.02 Mn |
| Dec 31, 2024 | 17.19 Mn |
| Dec 31, 2024 | 17.19 Mn |
| Sep 30, 2024 | 15.46 Mn |
| Sep 30, 2024 | 15.46 Mn |
| Jun 30, 2024 | 99,117.00 |
| Jun 30, 2024 | 99,117.00 |
| Mar 31, 2024 | 240,820.00 |
| Mar 31, 2024 | 240,820.00 |
| Dec 31, 2023 | 443,500.00 |
| Dec 31, 2023 | 443,500.00 |